JPH0251528B2 - - Google Patents

Info

Publication number
JPH0251528B2
JPH0251528B2 JP58139466A JP13946683A JPH0251528B2 JP H0251528 B2 JPH0251528 B2 JP H0251528B2 JP 58139466 A JP58139466 A JP 58139466A JP 13946683 A JP13946683 A JP 13946683A JP H0251528 B2 JPH0251528 B2 JP H0251528B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
application
nasal mucosa
lower alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58139466A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6032714A (ja
Inventor
Yoshiki Suzuki
Hiroshi Igura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Priority to JP58139466A priority Critical patent/JPS6032714A/ja
Priority to EP19850300205 priority patent/EP0187433B1/en
Publication of JPS6032714A publication Critical patent/JPS6032714A/ja
Priority to US07/153,527 priority patent/US4835142A/en
Publication of JPH0251528B2 publication Critical patent/JPH0251528B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP58139466A 1983-08-01 1983-08-01 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 Granted JPS6032714A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP58139466A JPS6032714A (ja) 1983-08-01 1983-08-01 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
EP19850300205 EP0187433B1 (en) 1983-08-01 1985-01-11 Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
US07/153,527 US4835142A (en) 1983-08-01 1988-02-04 Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58139466A JPS6032714A (ja) 1983-08-01 1983-08-01 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物

Publications (2)

Publication Number Publication Date
JPS6032714A JPS6032714A (ja) 1985-02-19
JPH0251528B2 true JPH0251528B2 (enExample) 1990-11-07

Family

ID=15245886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58139466A Granted JPS6032714A (ja) 1983-08-01 1983-08-01 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物

Country Status (2)

Country Link
US (1) US4835142A (enExample)
JP (1) JPS6032714A (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
JPH07140076A (ja) * 1993-11-12 1995-06-02 Bio Sensor Kenkyusho:Kk 粉体酸化剤組成物
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
CN1155368C (zh) * 1996-02-27 2004-06-30 帝人株式会社 鼻腔给药的粉剂组合物
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US20010053775A1 (en) * 1998-01-30 2001-12-20 Matthias Seidel Nasal solutions
JPH11246439A (ja) * 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
WO2000023023A1 (en) 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
WO2000074736A1 (en) 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
BR0108730A (pt) * 2000-02-28 2002-11-05 Vectura Ltd Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
US6881731B1 (en) * 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
HU229344B1 (en) * 2001-02-27 2013-11-28 Evonik Roehm Gmbh Coating and binding agent for pharmaceutical formulations with improved storage stability
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
SI1663235T1 (sl) 2003-08-18 2013-12-31 Parion Sciences, Inc. Zaščiteni pirazinoilgvanidinski blokatorji natrijevega kanala
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
EP1668035A2 (en) * 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
CN103223160B (zh) * 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
KR101217680B1 (ko) * 2004-12-09 2013-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 산을 사용한 글루코코르티코이드 에스테르의 안정화
UA88663C2 (en) * 2004-12-09 2009-11-10 Баер Энимал Хелс Гмбх Stabilisation of glucocorticoid esters with acids
RU2437679C2 (ru) * 2004-12-09 2011-12-27 Байер Энимэл Хельс ГмбХ Стабилизация сложных эфиров глюкокортикоидов кислотами
DK200500028A (da) * 2005-01-07 2006-08-11 Hansen Richard Brinch Preparation for preventing or treating calcium deficiency conditions in mammals
EP1909834A2 (en) * 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
CA2631212A1 (en) * 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
US9241908B2 (en) * 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
AU2009246799B2 (en) 2008-02-26 2014-02-27 Parion Sciences, Inc. Poly aromatic pyrazinoylguanidine sodium channel blockers
PL2723176T3 (pl) 2011-06-27 2018-01-31 Parion Sciences Inc Chemicznie i metabolicznie stabilny dipeptyd o silnej aktywności blokera kanału sodowego
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
PE20151054A1 (es) 2012-12-17 2015-08-07 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3276959A (en) * 1963-08-08 1966-10-04 Hefa G M B H Stabilized steroid compositions
JPS54158435A (en) * 1978-06-05 1979-12-14 Nippon Shikizai Kogyo Kenkyusho:Kk Surface treatment
US4294952A (en) * 1978-11-30 1981-10-13 Hitachi Chemical Company, Ltd. Polyamide-imide resin and its production
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4289764A (en) * 1979-12-04 1981-09-15 Drythanol Ltd. Steroid compositions
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
US4835142A (en) 1989-05-30
JPS6032714A (ja) 1985-02-19

Similar Documents

Publication Publication Date Title
JPS6032714A (ja) 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
CA2496699C (en) Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
JPS6034925B2 (ja) 持続性鼻腔用製剤およびその製造法
EP1025859B1 (en) Powdery pernasal compositions
JP2770970B2 (ja) ペンタミジンを含有する医薬組成物
NZ515596A (en) Medicament compositions, based on anticholinergically effective compounds and beta-mimetics
KR970704422A (ko) 투여용 약제학적 조성물
JPH10500420A (ja) フルチカゾンプロピオネート処方物
JPS62281892A (ja) エストラジオ−ル−１７β−エステル
JP2000502365A (ja) 新規な組み合わせ
EP0187433B1 (en) Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
BR9710115B1 (pt) composiÇço aquosa farmacÊutica, e processo de preparaÇço de uma composiÇço aquosa farmacÊutica.
HU214914B (hu) Gáznyomás alatti csomagolások poli(oxi-etilén)-gliceril-oleátok alkalmazásával és eljárás azok előállítására
JPH11509854A (ja) 発泡性咀嚼錠剤
NO334076B1 (no) Fremgangsmåte for fremstilling av tørrpulverinhaleringssammensetninger og multidose tørrpulverinhalator
JP2021506897A (ja) フドステインのエアロゾル吸入用溶液製剤及びその製造方法
US6007834A (en) Nasal melatonin composition
JP2005132801A (ja) 口腔内崩壊錠
JPS63239221A (ja) アゼラスチン及びテオフイリン又はアゼラスチン及びβ類似物質を含有する相乗作用を有する医薬及びその製法
EP0969831A1 (en) Nasal melatonin composition
JPH11130660A (ja) 鼻腔内投与用水性懸濁製剤
US20030003057A1 (en) Methods for administering leuprolide by inhalation
JP5171102B2 (ja) 経鼻吸収用睡眠導入剤
CN113577059B (zh) 一种用于小儿哮喘的活性药物
KR870001374B1 (ko) 구강 또는 비강점막용 분말상 제약적 조성물의 제조방법